Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stock Report

Market Cap: US$14.0b

Intra-Cellular Therapies Management

Management criteria checks 3/4

Intra-Cellular Therapies' CEO is Sharon Mates, appointed in May 2002, has a tenure of 22.83 years. total yearly compensation is $10.09M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $149.12M. The average tenure of the management team and the board of directors is 6.4 years and 11.2 years respectively.

Key information

Sharon Mates

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage8.8%
CEO tenure22.8yrs
CEO ownership1.1%
Management average tenure6.4yrs
Board average tenure11.2yrs

Recent management updates

Recent updates

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition

Mar 05

What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies

Jan 13

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

Dec 30
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move

Dec 09

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

CEO Compensation Analysis

How has Sharon Mates's remuneration changed compared to Intra-Cellular Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$75m

Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$10mUS$892k

-US$140m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$228m

Dec 31 2022US$9mUS$849k

-US$256m

Sep 30 2022n/an/a

-US$298m

Jun 30 2022n/an/a

-US$321m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$7mUS$794k

-US$284m

Sep 30 2021n/an/a

-US$259m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$232m

Dec 31 2020US$5mUS$767k

-US$227m

Sep 30 2020n/an/a

-US$207m

Jun 30 2020n/an/a

-US$187m

Mar 31 2020n/an/a

-US$160m

Dec 31 2019US$5mUS$745k

-US$148m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$154m

Dec 31 2018US$4mUS$723k

-US$155m

Compensation vs Market: Sharon's total compensation ($USD10.09M) is about average for companies of similar size in the US market ($USD13.02M).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.

CEO

Sharon Mates (71 yo)

22.8yrs

Tenure

US$10,086,413

Compensation

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...

Leadership Team

NamePositionTenureCompensationOwnership
Sharon Mates
Co-Founder22.8yrsUS$10.09m1.07%
$ 149.1m
Michael Halstead
President1yrUS$3.53m0.020%
$ 2.8m
Suresh Durgam
Executive VP & Chief Medical Officer6.6yrsUS$3.51m0.040%
$ 5.6m
Mark Neumann
EVP & Chief Commercial Officer6.4yrsUS$3.54m0.050%
$ 6.9m
Sanjeev Narula
Executive VPless than a yearno datano data
Robert Davis
Senior VP & Chief Scientific Officer9.3yrsUS$2.13mno data
Juan Sanchez
Vice President of Corporate Communications & Investor Relations11yrsUS$1.38mno data
Karen Sheehy
Senior VP & Chief Compliance Officer5.7yrsno datano data
John Condon
Senior Vice Presidentno datano datano data
Michael Olchaskey
Senior VP & Head of Regulatory Affairs6.5yrsno datano data
John Bardi
Senior VP of Market Access6yrsno datano data
Willie Earley
Senior VP & Head of Clinical Development2.9yrsno datano data

6.4yrs

Average Tenure

60.5yo

Average Age

Experienced Management: ITCI's management team is seasoned and experienced (6.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sharon Mates
Co-Founder11.6yrsUS$10.09m1.07%
$ 149.1m
Rory Riggs
Independent Director11.2yrsUS$470.51k0.12%
$ 17.3m
Robert Van Nostrand
Lead Independent Director11.2yrsUS$507.58k0.011%
$ 1.5m
Joel Marcus
Independent Director11.6yrsUS$473.34k0.045%
$ 6.3m
Carol Tamminga
Chairman of Medical Advisory Boardno datano datano data
John Kane
Member of Medical Advisory Boardno datano datano data
Jeffrey Lieberman
Member of Medical Advisory Boardno datano datano data
Christoph Correll
Member of Medical Advisory Boardno datano datano data
Donald Goff
Member of Medical Advisory Boardno datano datano data
Eduardo Salas
Independent Director2.9yrsUS$461.30k0.0015%
$ 205.3k

11.2yrs

Average Tenure

71yo

Average Age

Experienced Board: ITCI's board of directors are seasoned and experienced ( 11.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 04:16
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intra-Cellular Therapies, Inc. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Jason Matthew GerberryBofA Global Research
Robert HazlettBTIG